![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Lipton Allan
Publisher: Informa Healthcare
ISSN: 1472-8214
Source: Expert Opinion on Emerging Drugs, Vol.8, Iss.2, 2003-11, pp. : 469-488
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Bisphosphonate Therapy in the Treatment of Multiple Myeloma
Current Pharmaceutical Design, Vol. 16, Iss. 27, 2010-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Safety of Long-Term Bisphosphonate Therapy for the Management of Osteoporosis
Drugs, Vol. 71, Iss. 6, 2011-04 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Alternative Use of Bisphosphonate Therapy for Rheumatic Disease
Current Pharmaceutical Design, Vol. 16, Iss. 27, 2010-09 ,pp. :